Wall Street analyst estimates for Johnson & Johnson (JNJ): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Valuation Ratios
| P/E Ratio | 30.82 |
| Price / Book | 7.66 |
| EV / EBITDA | 19.87 |
| Dividend Yield | 1.98% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.89B | $76.45B | $81.58B | $82.06B | $82.58B | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
| Cost of Revenue | $21.79B | $25.44B | $27.09B | $27.56B | $28.43B | $23.40B | $24.60B | $26.55B | $27.47B | $30.26B |
| Gross Profit | $50.10B | $51.01B | $54.49B | $54.50B | $54.16B | $55.34B | $55.39B | $58.61B | $61.35B | $63.94B |
| Research & Development | $9.14B | $10.59B | $10.78B | $11.36B | $12.34B | $14.28B | $14.13B | $15.09B | $17.23B | $14.66B |
| Selling, General & Admin | $20.07B | $21.52B | $22.54B | $22.18B | $22.08B | $20.12B | $20.25B | $20.11B | $21.97B | $23.68B |
| Operating Expenses | $29.21B | $32.11B | $33.31B | $33.53B | $34.42B | $34.40B | $34.38B | $35.20B | $39.20B | $38.34B |
| Operating Income | $20.89B | $18.90B | $21.18B | $20.97B | $19.73B | $20.94B | $21.01B | $23.41B | $22.15B | $25.60B |
| EBITDA | $24.28B | $24.25B | $25.93B | $24.66B | $23.93B | $26.75B | $26.61B | $23.32B | $24.78B | $41.05B |
| Interest Expense | $726.0M | $934.0M | $1.00B | $318.0M | $201.0M | $183.0M | $276.0M | $772.0M | $755.0M | $971.0M |
| Pre-tax Income | $19.80B | $17.67B | $18.00B | $17.33B | $16.50B | $19.18B | $19.36B | $15.06B | $16.69B | $32.58B |
| Income Tax | $3.26B | $16.37B | $2.70B | $2.21B | $1.78B | $1.38B | $2.99B | $1.74B | $2.62B | $5.78B |
| Net Income | $16.54B | $1.30B | $15.30B | $15.12B | $14.71B | $20.88B | $17.94B | $35.15B | $14.07B | $26.80B |
| EPS | $6.08 | $0.48 | $5.75 | $5.74 | $5.59 | $7.93 | $6.83 | $13.88 | $5.84 | $11.03 |
| EPS (Diluted) | $5.93 | $0.47 | $5.61 | $5.63 | $5.51 | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Shares Outstanding (Diluted) | $2.79B | $2.75B | $2.73B | $2.68B | $2.67B | $2.67B | $2.66B | $2.56B | $2.43B | $2.43B |
Price
| Price | $267.28 |
| Market Cap | $644.1B |
| Exchange | NYSE |
| Country | US |
Related companies: ABBV · AMGN · AZN · GILD · MRK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of JNJ: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks